Opko Health (OPK) Reports No Statistically Significant Data Observed in Lagova Phase 2 as Pediatric GHD Treatment
Tweet Send to a Friend
OPKO Health, Inc. (NYSE: OPK) yesterday hosted a webcast presenting outstanding interim six-month results from a Phase 2 study of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
